NASDAQ : QTTB

Q32 Bio Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 8.87 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 264.06M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.

Details

NameQ32 Bio Inc.
SectorHealthcare
IndustryBiotechnology
Employees22
Founded2015
CeoJodie Morrison
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS7469641051
Cusip746964105
Cik1661998
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Jodie Pope MorrisonChief Executive Officer and Director
Lee H. Kalowski M.B.A.Chief Financial Officer and President
Dr. Shelia M. Violette Ph.D.Co-founder, Chief Scientific Officer and President of Research
David Appugliese J.D.Senior Vice President and Head of People
Maria Marzilli M.P.H.Chief Business Officer
Dr. José M. Trevejo M.D., Ph.D.Chief Medical Officer
Dr. Elham Hershberger Pharm.D.Chief Development Officer

Contact

Address830 Winter Street, Waltham, Massachusetts 02451, United States
Phone781 999 0232
Websitehttps://www.q32bio.com